Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

COVID-19 Resurgence Accelerates Diagnostic Testing: 3 Top Picks

By Zacks Investment ResearchStock MarketsMar 31, 2021 09:18PM ET
www.investing.com/analysis/covid19-resurgence-accelerates-diagnostic-testing-3-top-picks-200570792
COVID-19 Resurgence Accelerates Diagnostic Testing: 3 Top Picks
By Zacks Investment Research   |  Mar 31, 2021 09:18PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

The pandemic-hit investment world, during the process of finding COVID-proof profitable sectors, has by now recognized MedTech’s unabated and nuanced growth trend. During the pre-pandemic era, this sector, with limited success history, was never one for big betting. COVID-19 challenges however have changed the investment landscape, making MedTech one of the safest and profitable hunting grounds for investors.

The MedTech sector started witnessing a steady rebound from the second half of 2020, thanks to a number of positive developments, including a series of COVID-19 diagnostic test launches and a large-scale shift of consumer preference toward digital healthcare options. The solid uptick in the non-COVID product portfolio and emergency medical services also aided the fast recovery of the sector.

COVID-19 Testing Demand Continues in 2021

It was initially thought that with mass-scale vaccine rollout, COVID-19 testing makers will gradually lose their ground. However, with the renewed wave of coronavirus cases along with emergence of new mutant strains, diagnostic laboratories are once again overwhelmed by the enormous pressure of developing COVID-19 test kits.

Government Initiatives

Earlier this year, the Centers for Disease Control and Prevention (CDC) had announced that The Department of Health and Human Services (HHS) will offer more than $22 billion of funding to states, localities, and territories to support the nation’s response to the COVID-19 pandemic. This is as directed by the Coronavirus Response and Relief Supplemental Appropriations Act.

From this amount, $19 billion will be used to support testing, contract tracing, surveillance, containment, and mitigation to monitor and suppress the spread of COVID-19.

One-Year Price Performance

Not only this, the President’s recently-passed $1.9 trillion American Rescue Plan includes $400 billion of funding for critical measures to slow down the spread of the infection.

Federal Tie-Ups With Testing Companies

At this point, government representatives are going all out to increase the nation’s testing capacity and forming federal-private tie ups to increase COVID-19 testing volume. Abbott ABT recently completed its promised supply of 150 million BinaxNOW COVID-19 tests to the government. In a major development earlier this week, this rapid antigen self test received the FDA’s Emergency Use Authorization (EUA) for over-the-counter, non-prescription, asymptomatic use.

Quest Diagnostics DGX in January 2020 entered into a mega-testing deal to aid public health response to COVID-19. This public and private collaboration is expected to help CDC to come up with a large-scale longitudinal genomic survey of the SARS-CoV-2 virus using Quest Diagnostics’ COVID-19 testing data and patient samples across the United States.

Beckton Dickinson and Companyor BD BDX announced a $24 million investment in August 2020 by the Department of Defense (DOD) in collaboration with the HHS to support the scale up of U.S. manufacturing capabilities for BD Veritor Solution for Rapid Detection of SARS-CoV-2. Later in November, BD received an order from the government of Canada for 7.6 million tests through March 2021 to support the country’s planning of an advanced COVID-19 testing strategy.

Best Diagnostic Testing Stocks to Buy Now

The above developments show that there couldn’t be a better time to invest in diagnostic testing stocks. We have narrowed down our search to the following stocks based on a favorable Zacks Rank and strong prospects for 2021.

Fulgent Genetics (NASDAQ:FLGT) FLGT: Fulgent was recognized as the #1 provider of COVID-19 tests in California by California Department of Public Health in late January, processing the highest volume in tests. In terms of COVID-19 testing capabilities, the company noted that its tests have been detecting all major mutations of the virus.

For 2021, the Zacks Consensus Estimate for revenues indicates an improvement of 90.1% from the prior-year period. In the past year, this Zacks Rank #1 (Strong Buy) company shares have gained 863.3%, outperforming the Medical industry’s rally of 22.5%.

You can see the complete list of today’s Zacks #1 Rank stocks here.

Bio-Rad Laboratories (NYSE:BIO) BIO: The company is consistently witnessing an uptick in polymerase chain reaction (PCR), Droplet Digital PCR (ddPCR) and Process Media product revenues, resulting from robust demand due to COVID-19 testing and related research. Continued momentum of the ddPCR business looks encouraging. The recent receipt of the FDA’s EUA for COVID-19, influenza A and influenza B RT-PCR (Reverse transcription PCR) syndromic multiplex test along with another EUA for the company’s COVID RT-PCR assay kit (obtained in January this year) look encouraging.

For 2021, the Zacks Consensus Estimates for revenues and earnings indicates an improvement of 5.2% and 6.9% respectively from the prior-year period. Year to date, this Zacks Rank #2 (Buy) company’s shares have gained 58.3%.

IDEXX Laboratories IDXX: The company’s human health business, OPTI Medical Systems’ COVID-19 human PCR testing is currently strongly contributing to its top line. Further, amid the pandemic-led restrictions, IDEXX is witnessing a sequential improvement in Companion Animal Group instrument placements.

For 2021, the Zacks Consensus Estimates for revenues and earnings indicates an improvement of 14.3% and 13.1% respectively from the prior-year period. Over the past year, this Zacks Rank #2 company’s shares have gained 104.1%.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.

Click here for the 4 trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Becton, Dickinson and Company (BDX): Free Stock Analysis Report

Quest Diagnostics Incorporated (NYSE:DGX): Free Stock Analysis Report

Abbott Laboratories (NYSE:ABT): Free Stock Analysis Report

BioRad Laboratories, Inc. (BIO): Free Stock Analysis Report

IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report

FULGENT GENETIC (FLGT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research
COVID-19 Resurgence Accelerates Diagnostic Testing: 3 Top Picks
 

Related Articles

Guy S. Ortmann, CMT
Trends Turn Positive By Guy S. Ortmann, CMT - Jul 30, 2021

McClellan OB/OS Oscillators Remain Neutral All the major equity indexes closed higher Thursday with positive internals on the NYSE and NASDAQ as trading volumes declined on both...

COVID-19 Resurgence Accelerates Diagnostic Testing: 3 Top Picks

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email